Table 5. Genes where betweenness-centrality was enriched among one sub-group relative to another.
| Gene | Control (n = 19) | Experimental (n = 21) | Z > 1 (n = 10) | Z > 2 (n = 5) |
|---|---|---|---|---|
| SF3A2 | 37.5% | 47.6% | 60.0% | 100.0% |
| ESR1* | 25.0% | 38.1% | 50.0% | 80.0% |
| BIRC5 | 37.5% | 47.6% | 70.0% | 80.0% |
| MDM2 | 6.3% | 23.8% | 30.0% | 60.0% |
| STAT1* | 0.0% | 14.3% | 30.0% | 60.0% |
| POLR2H | 18.8% | 28.6% | 50.0% | 60.0% |
| CTNNB1 | 6.3% | 9.5% | 20.0% | 40.0% |
| CREBBP | 0.0% | 14.3% | 30.0% | 40.0% |
| RAC1 | 0.0% | 14.3% | 30.0% | 40.0% |
| JUN | 6.3% | 19.0% | 40.0% | 40.0% |
| FOS | 6.3% | 14.3% | 20.0% | 40.0% |
| STAT3 | 6.3% | 19.0% | 20.0% | 40.0% |
| IL8 | 0.0% | 9.5% | 20.0% | 40.0% |
| NFKBIA* | 0.0% | 9.5% | 20.0% | 40.0% |
| BRCA1 | 50.0% | 33.3% | 40.0% | 20.0% |
| HDAC1 | 37.5% | 14.3% | 10.0% | 0.0% |
| CDK5 | 0.0% | 23.8% | 30.0% | 0.0% |
| SDC2* | 18.8% | 19.0% | 30.0% | 0.0% |
For example, SF3A2 was considered critical in 37.50% of sub-networks in the control group, but 100% of experimental networks with Z > 2. Shown here are genes where the disparity was at least 25 percentage points between most-enriched and least-enriched. Many of these nodes are enriched in the highest-scoring networks and may be critical nodes specific to metformin’s anti-cancer activity. *indicates genes which have known carcinogenic mutations that could significantly alter the networks